XRCC1 and ovarian carcinoma: In human ovarian cancer we have recently demonstrated that tumours frequently over-express XRCC1 (48%) and significantly associated with higher stage (p = 0.006), serous type tumours (p = 0.008), sub-optimal de-bulking (p = 0.004), a two fold increase of risk of death (p = 0.007) and progression (p<0.0001) [17].